Guillain–Barré syndrome in a cancer patient treated with bevacizumab

Guillain GC, Barre ́ JA, Strohl A (1916) Sur un syndrome de radiculone ́vrite avec hyperalbuminose du liquid ce ́phaloachidien sans reaction cellulaire: remarues sur les caracte`re cliniques et graphiques des reflexes tendi- neux. Bull Soc Med Hop Paris 40:1462–1470

Yuki N, Hartung H (2012) Guillain–Barré syndrome. N Engl J Med 366:2294–2304

Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol 27:S21–S24

Fokke C, van den Berg B, Drenthen J et al (2014) Diagnosis of Guillain–Barre ́ syndrome and validation of Brighton criteria. Brain 137:33–43

Poropatich KO, Fischer Walker CL, Black RE (2010) Quantifying the association between Campylobacter infection and Guillain–Barré syndrome: a systematic review. J Health Popul Nutr 28:545–552

Hadden RD, Karch H, Hartung HP et al (2001) Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 56:758–765

Vigliani MC, Magistrello M, Polo P et al (2004) Risk of cancer in patients with Guillain–Barré syndrome (GBS). A population-based study. J Neurol 251:321–326

Lagrange E, Veran O, Besson G (2007) Pure motor relapsing Guillain–Barré syndrome associated with anti-GM1 antibodies revealing urinary bladder cancer. Eur J Neurol 17:e7

Myers SE, Williams SF (1994) Guillain-Barré syndrome after autologous bone marrow transplantation for breast cancer: report of two cases. Bone Marrow Transplant 13:341–344

Christodoulou C, Anastasopoulos D, Visvikis A et al (2004) Guillain–Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy. Anticancer Drugs 15:997–999

Hiew FL, Rajabally YA (2017) Malignancy in Guillain—Barré syndrome: a twelve-year single-center study. J Neurol Sci 375:275–278

Kuwahara M, Samukawa M, Ikeda T et al (2017) Characterization of the neurological diseases associated with Mycoplasma pneumoniae infection and anti-glycolipid antibodies. J Neurol 264:467–475

Sullivan HC, Edgar MA, Cohen C et al (2015) The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases. J Clin Pathol 68:44–50

Kahn HJ, Bailey D, Marks A (2002) Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s Sarcoma and a subset of angiosarcomas. Mod Pathol 15:434–440

Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain–Barré syndrome. Lancet 388:717–727

Samukawa M, Kuwahara M, Morikawa M et al (2016) Electrophysiological assessment of Guillain–Barré syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type. J Neuroimmunol 301:61–64

Zambonin V, De Toma A, Carbognin L et al (2017) Clinical results of randomized trials and ‘real-world’ data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research. Expert Opin Biol Ther 17:497–506

Ray-Coquard IL, Domont J, Tresch-Bruneel E et al (2015) Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol 33:2797–8202

Liu P (2012) Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment. J Community Hosp Intern Med Perspect 2:17217